Angiex, Inc.
Angiex is dedicated to developing first-in-class Nuclear-Delivered Antibody-Drug Conjugates™ (ND-ADCs) to address the hallmarks of cancer lethality and deliver safe and effective cancer therapies. Their mission is to exploit novel biology to gain revolutionary power over cancer, aiming to make cancer a non-lethal disease. Based in Cambridge, Massachusetts, Angiex was founded by experts in angiogenesis, vascular biology, and oncology. Their lead product, AGX101, is progressing through clinical trials, with a pipeline of additional ND-ADCs in development.
Industries
Nr. of Employees
small (1-50)
Products
Lead TM4SF1-directed nuclear-delivered antibody-drug conjugate (lead ND-ADC)
A first-in-class antibody–drug conjugate designed to target the TM4SF1 cell-surface transporter expressed on tumor cells and tumor vasculature and to deliver a cytotoxic payload into the nucleus or cytosol.
Lead TM4SF1-directed nuclear-delivered antibody-drug conjugate (lead ND-ADC)
A first-in-class antibody–drug conjugate designed to target the TM4SF1 cell-surface transporter expressed on tumor cells and tumor vasculature and to deliver a cytotoxic payload into the nucleus or cytosol.
Services
Preclinical development and IND-enabling studies
Discovery-to-IND preclinical activities including target validation, potency assays, xenograft efficacy studies, and safety/pharmacology experiments.
Early-phase clinical development support
Design and execution support for Phase I open-label dose-escalation and expansion clinical trials to evaluate safety, pharmacokinetics, and preliminary anti-tumor activity.
CDMO coordination for clinical supply and bioconjugation
Management and coordination of outsourced bioconjugation and cGMP manufacture of clinical trial material through contract manufacturing partners.
Preclinical development and IND-enabling studies
Discovery-to-IND preclinical activities including target validation, potency assays, xenograft efficacy studies, and safety/pharmacology experiments.
Early-phase clinical development support
Design and execution support for Phase I open-label dose-escalation and expansion clinical trials to evaluate safety, pharmacokinetics, and preliminary anti-tumor activity.
CDMO coordination for clinical supply and bioconjugation
Management and coordination of outsourced bioconjugation and cGMP manufacture of clinical trial material through contract manufacturing partners.
Expertise Areas
- Antibody-drug conjugate development
- Target discovery and validation (TM4SF1)
- Oncology preclinical models and in vivo efficacy
- Intracellular/nuclear delivery strategies
Key Technologies
- Antibody-drug conjugation
- Nuclear delivery / intracellular trafficking assays
- In vitro potency assays
- Human tumor xenograft models